Provided by Tiger Trade Technology Pte. Ltd.

ANI Pharmaceuticals

81.84
+0.34000.42%
Post-market: 81.840.00000.00%18:09 EST
Volume:301.81K
Turnover:24.56M
Market Cap:1.84B
PE:48.86
High:82.42
Open:82.42
Low:80.57
Close:81.50
52wk High:99.50
52wk Low:54.10
Shares:22.47M
Float Shares:20.38M
Volume Ratio:0.87
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.67
EPS(LYR):-1.0429
ROE:8.66%
ROA:2.37%
PB:3.64
PE(LYR):-78.47

Loading ...

ANI Pharmaceuticals (ANIP) Is Up 11.2% After Raising 2026 Revenue Outlook And Rare Disease Hiring Plan – Has The Bull Case Changed?

Simply Wall St.
·
Jan 17

ANI Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
Jan 16

ANI Pharmaceuticals Sr. VP Meredith Cook Reports Sale of Common Shares

Reuters
·
Jan 15

Guggenheim Reaffirms Their Buy Rating on ANI Pharmaceuticals (ANIP)

TIPRANKS
·
Jan 13

ANI Pharmaceuticals issues strong 2025 preliminary results, 2026 outlook

TIPRANKS
·
Jan 13

ANI Pharmaceuticals Shares up 10.6% Premarket After Forecasting FY26 Revenue Above Estimates

THOMSON REUTERS
·
Jan 12

GUIDANCE: (ANIP) ANI Pharmaceuticals Expects 2026 Revenue Range $1.06B - $1.12B, vs. FactSet Est of $955.1M

MT Newswires Live
·
Jan 12

BRIEF-ANI Pharmaceuticals Q4 Revenue USD 111.4 Million Vs. IBES Estimate USD 225.2 Million

Reuters
·
Jan 12

ANI Pharmaceuticals Projects Up to $1.115 Billion in 2026 Revenue

Reuters
·
Jan 12

ANI Pharmaceuticals Inc FY2026 Shr View $8.56, REV View $955.1 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
Jan 12

ANI Pharmaceuticals Inc - 2025 Adj Non-Gaap Diluted EPS Expected $7.37 to $7.64

THOMSON REUTERS
·
Jan 12

ANI Pharmaceuticals Outlook FY Adjusted Ebitda USD 275-290 Million

THOMSON REUTERS
·
Jan 12

Corrected- ANI Pharmaceuticals Q4 Cortrophin Gel (Not Total Co) Revenue USD 111.4 Million (Removes Q4 Revenue Estimate)

THOMSON REUTERS
·
Jan 12

ANI Pharmaceuticals Inc - 2025 Net Revenues Expected Between $854 Mln and $873 Mln

THOMSON REUTERS
·
Jan 12

ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities

THOMSON REUTERS
·
Jan 12

ANI Pharmaceuticals (ANIP) Valuation Check After Robust 2025 Results And Raised Guidance

Simply Wall St.
·
Jan 10

ANI Pharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference

Reuters
·
Jan 07

ANI Pharmaceuticals SVP Chief HR Officer Krista Davis Reports Sale of Common Shares

Reuters
·
Dec 20, 2025

ANI Pharmaceuticals (ANIP): Assessing Valuation After Recent Share Price Momentum

Simply Wall St.
·
Dec 20, 2025

Is ANI Pharmaceuticals Still Attractively Priced After Its Strong Multi Year Share Price Run?

Simply Wall St.
·
Dec 15, 2025